Partial and whole gene deletions represent a large proportion (4 -33%) of the APC mutations found in polyposis patients, who previously had negative test results. The genotype -phenotype correlations for these APC deletions have not been studied in detail. We aimed to assess the number of germ line APC deletions in Dutch polyposis patients, to describe the clinical phenotype(s), and to review the current literature. We screened 296 index patients with polyposis, who previously had negative test results for APC or MUTYH mutations, for germ line APC gene deletions using Multiplex Ligation-dependent Probe Amplification. APC deletions were identified in 19 polyposis patients; seven had a whole gene deletion, nine had a deletion involving two or more exons, and three had single exon deletions. Most of the deletion families (83%) displayed a classic familial adenomatous polyposis (FAP) phenotype (100 -2000 adenomas). We saw no patients with APC deletions and a severe phenotype (ie 42000 polyps); on the contrary, two families carrying a deletion of exons 7-13 and one family with a deletion of exons 1-5 showed a distinctly attenuated FAP phenotype. APC deletions were found in a considerable proportion of polyposis patients previously tested negative for APC or MUTYH (6%, 19/296) and represent 8% of all APC mutations found at our clinics (19/242). Methods to identify such deletions should therefore be included in routine germ line APC mutation analysis. While most total and partial APC deletions lead to a classic FAP phenotype, specific (in-frame) deletions may lead to an attenuated polyposis phenotype.
Introduction
Familial adenomatous polyposis, FAP (MIM175100), is an autosomal dominant inherited disease caused by germ line mutations in the APC gene; it affects approximately one in 13 500 people. 1 Mutation carriers are predisposed in the majority of cases to develop hundreds or even thousands of polyps and subsequently go on to develop colorectal cancer (CRC). 1, 2 In addition, extracolonic features such as fundic gland polyps (FGP), duodenal polyps, congenital hypertrophy of the retinal pigment epithelium (CHRPE) and desmoid tumors are often present, while a more attenuated form of FAP has also been described in which patients develop less than a hundred polyps at a relatively late age. 3 Another inheritable form of polyposis is caused by recessive mutations of the MUTYH gene. 4 MUTYHassociated polyposis (MAP) is found in 10 -20% of polyposis patients. 5 -7 The APC gene is a relatively large gene, containing 15 exons and encoding a protein of 2843 amino acids. Exon 15 is by far the largest exon containing over three-quarters of the coding sequence. 8 Depending on clinical features and mutation detection techniques applied, germ line mutations in the APC gene are found in 30 -80% of patients with polyposis 2,9,10 and most APC mutations occur in the 5 0 half of its coding region. Genotypephenotype relations have been reported extensively for small nucleotide alterations (point mutations). A classic phenotype (ie 100 -2000 polyps) is associated with mutations in codon 168 -1250 (exons 4/5 -exon 15) or codon 1400 -1580 (exon 15). Mutations occurring between codon 1250 and 1464 (exon 15) , but particularly at codon 1309; 2, 11 lead in most cases to a more severe phenotype (42000 polyps at a relatively young age). A more attenuated form of polyposis is associated with mutations in three regions: (i) in the 5' part of the APC gene; (ii) alternative spliced region in exon 9 and (iii) mutations in the extreme 3 0 site of the gene. 12, 13 Partial and whole gene deletions have been shown to represent a large proportion (4 -33%) of APC mutations in polyposis patients who previously had negative test results. 14 -17 Large deletions have also been found in other oncogenes such as BRCA1, BRCA2, MLH1, MSH2 and MSH6. 17 -20 Recently, APC duplications of exon 4 and 15
have also been described in FAP patients. 21, 22 Using the new MLPA (Multiplex Ligation-dependent Probe Amplification) technique, 23 we searched for deletions of the whole gene of one or more exons in 296 APCand MUTYH-negative index patients with polyposis. Here we report on genotype -phenotype correlations in 19 index patients with identified deletions and review the current literature on APC deletions.
Patients and methods
Between 1995 and 2005, a total of 599 index polyposis patients were referred for FAP testing to the Molecular Genetics Laboratory, Center for Human and Clinical Genetics (Leiden, The Netherlands). Informed consent was obtained for DNA testing according to protocols approved by LUMC Ethics Review Board. The 599 index patients were all screened for germ line mutations in the APC gene by DGGE, PTT and sequence analysis. In 223/599 patients, we were able to identify a pathogenic APC mutation (37%). Mutations in the APC gene involve frameshift mutations (n ¼ 124, 55%), nonsense mutations (n ¼ 70, 31%) or splice mutations (n ¼ 26, 12%), and three large cytogenetically detected deletions (cytogenetic analysis is only done when developmental disorders are present).
In 296 polyposis index patients with available DNA, in whom no APC mutations were detected and MUTYH was ruled out in most of the cases (225/296), we went on to perform MLPA to look for APC deletions.
For MLPA, the P043 kit was used (http://www. mrc-holland.com). This kit contains 20 probes covering the APC region, three probes for the promoter regions, 14 for exons 1 -14 and three for exon 15. The MLPA analysis was performed according to the MRC Holland protocol 23 with some adaptation: all reagents in the kit were used at 1/ 4 of the advised volume and hybridization time was cut from 16 to 2.5 h. To exclude false-positive results due to variants underlying the probe, single exon deletions containing only one MLPA probe (exons 11 and 14) were confirmed by a long-range PCR (see Figure 1) We describe the clinical details of Dutch index cases and their family members. Furthermore, we combined our results for index cases with whole and partial APC gene deletions with those of previous studies. For this, we searched the PubMed and EMBASE databases up to December 2006 using the terms 'Adenomatous Polyposis Coli', 'Genes, APC', 'Gene Deletion', 'Gene Dosage', 'Gene Disruption, 'Gene Loss' and 'Gene Dosage', with relevant Figure 1 Two single-exon deletions (exons 11 and 14) confirmed by long-range PCR. An agarose gel shows the PCR products of two families with an exons 11 and 14 deletion, respectively (left), compared with controls (centre and right). In the patients, a smaller second fragment is also visible besides the normal product. WT, wild type; del, deletion. BrC, breast cancer; C, caecum; CA, colon ascendens; CHRPE congenital hypertrophy of the retinal pigment epithelium; CRC, colorectal cancer; DA duenal adenomas/polyps; EC, epidermoid cysts; F, female; FAP, familiar adenomatous polyposis; FGP, fundic gland polyps; LuC, lung cancer; M, male; ND, no data; PrC, prostate carcinoma; R, rectum; S, sigmoid. In all cases in which exon 1 was deleted, the promoter region was also deleted. Families of cases 8 and 12 have been reported previously. The index patients 9 and 10 developed less than 100 polyps, but they were young (27 and 20 years old, respectively) and were therefore classified as classic FAP. In cases 16 and 17, the index patients developed between 50 and 100 polyps at the ages of 36 and 44 years, respectively, but since a majority of family members showed a classic phenotype, both families were classified as classic. Two cases (11 and 12) with exons 7 -13 deletion, and one case 8 with an exons 1 -5 deletion had an apparently attenuated phenotype. Five (1, 2, 5, 9 and 14) of 18 index patients (28%) were apparently de novo cases, because parents and siblings had no polyps or CRC; in one case, no family history was available. In five index cases (7, 9, 10, 14 and 16) and seven family members, extra colonic features such as duodenal adenomas, FGP and/or epidermoid cysts were diagnosed. Other FAP-related manifestations in family members included a deletion carrier with hepatoblastoma (case 4) and a deletion carrier with duodenal carcinoma (case 10). One index patient (case 19) developed breast cancer twice at age 40 and 47 years, histologically defined as an adenocarcinoma (no further details could be retrieved) and a ductal adenocarcinoma, respectively, and a small-cell lung cancer at age 51. None of the families showed developmental disorders, which might be an indication of a deletion extending beyond the APC gene, although in case 13, two family members with an exons 9 -15 deletion had a learning disability and one also had epilepsy.
Deletion of exons 7 -13 is an in-frame deletion, because this region contains an exact threefold of nucleotides (corresponding with the codons), deletions of exons 4 -5, 11 and 14 are out of frame. The in-or out-of-frame status in deletions including the promoter region and/or exon 15 cannot be predicted because it is not known to what extend these deletions reach.
Discussion
We identified 19 large APC deletions in a MPLA screening of 296 polyposis patients in whom no APC and MUTYH mutations were detected: seven whole gene deletions, nine deletions of two or more exons and three single exon deletions. Most cases had classic polyposis, none could be classified as severe, and three families had AFAP. Remarkably, the 7 -13 deletion found in two AFAP families is an in-frame deletion, and we therefore studied the literature to determine possible genotype -phenotype correlations in APC deletion carriers.
Up to August 2006, a total of 89 submicroscopic APC gene deletions, including this series of patients, were reported using MLPA, PCR and real-time PCR, quantitative PCR, polymorphic markers, and cDNA analysis. 14 -17,22,24 -33 The reported deletions are summarized in Figure 2 and clinical details are given in 32 ie, a proband with less then 70 polyps and CRC at an age of 65 years old. In six further whole gene deletion cases, the number of polyps was described as 'multiple', which is generally reserved for a polyp count of less than 100, although patients were classified by the authors as 'typical' and 'FAP', probably because of their young age at presentation.
14,17
Partial deletions Including our cases, a total of 42 partial APC gene deletions have been reported in the literature. The most frequent deletions were exons 14 (n ¼ 6), 14 -15 (n ¼ 4), 15 (n ¼ 4), 8 -15 (n ¼ 4) and 9 -15 (n ¼ 4). Most cases with partial APC deletions were classified as classic FAP. We found three index cases with an attenuated phenotype (8, 11 and 12) family with an exon 4 deletion with an index patient who had 300 polyps at the of age 69 years. The in-or out -of-frame status of the APC deletion could be relevant for the phenotype of APC deletion patients, as this is a well-known phenomenon in Duchenne and Becker dystrophies. 34 If the deletion is in-frame, a shorter but possibly functional APC product can be produced. The exons 7 -13 deletion is an in-frame deletion, because this region contains an exact threefold of nucleotides (corresponding with the codons), possibly thereby explaining the milder phenotype. The in-or out-of-frame status in deletions including the promoter region and/or exon 15 could not be predicted. Without these regions, whether or not in-or out-of-frame, it is very unlikely that a functional APC product will be made. The promoter region is needed for starting transcription and exon 15 contains seven 20 amino acid repeats and three 15 amino acid repeats that are essential for regulating the b-catenin turnover and localization. 35, 36 In our two AFAP families with a 7 -13 deletion, the deletion was in frame. All the other partial deletions (without the promoter region or exon 15) reported here and in the literature were out frame. The diversity of the reported deletions does not indicate the presence of 'hot spot' breakpoints. We also found that the size of the exon 14 deletion in our study was larger than that reported by Aretz et al 14 (2.6 versus 2.0 kb), indicating at least one different breakpoint. More breakpoints should be expected in large introns, but we did not find any relation between the length of the intron (ranging from 681 to 14 111 nucleotides (http://www.ensembl.org/, Gene ID ENSG00000134982) and the number of breakpoints (P ¼ 0.4 for trend, Pearson's R). For this analysis, we included only studies that had looked for deletions in all the exons separately using MLPA. 14, 17, 24, 28, 29, 33 Colorectal Cancer Almost half of our patients developed colon cancer (44%, 8/18), one patient with a whole gene deletion had two 
(1) Figure 2 Exon deletions reported in our series and by previous studies. 14 -17,22,24 -33 The deletions found in this study are given between brackets. Deletions due to proven splice site mutations were not included. The exact breakpoint (in introns) of most deletions was not described exactly; the exonic deletions are shown here. 14, 17, 24, 28, 29 ; Linkage: 24, 40 ; (Semi) quantitative/double competitive PCR: 15, 26, 27 ; Real-time PCR: 16, 22, 32 ; cDNA analysis: 30, 31, 40 . aA Refers to this study.
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synchronous carcinomas, and in one patient no clinical data were available. Five of the nine carcinomas were located in the distal part of the colon (55%).
Combining our results with those from previous studies (see Table 2 ), we found no significant difference between partial and whole gene APC deletions for the occurrence of CRC. In 39 whole gene deletion cases with detailed clinical information, nine CRCs were found (23%) with a mean age of 40 years (range: 31 -65). In 33 cases with one or more exon deletions -for whom detailed clinical information was reported -8 (24%) developed colon cancers with a mean age of 29 years (range: 29 -45). The actual risk for developing CRC is most probably higher than this 23 -24%, since a large number of cases will probably have undergone colectomy at a younger age (ie o30 years) to prevent the development of CRCs.
Extracolonic manifestations
We saw no essential difference between partial and whole gene APC deletions for the occurrence of extracolonic manifestations when we combined our results with those of previous studies (a total of 39 patients with whole APC gene deletions and 33 patients with partial exon deletions had available clinical data). Fourteen out of these 39 index cases (36%) had one or more extracolonic features, that is duodenal adenomas (n ¼ 6), duodenal cancer (n ¼ 1), FGP (n ¼ 5), CHRPE (n ¼ 3), desmoids (n ¼ 4), osteomas (n ¼ 5) and epidermoid cysts (n ¼ 2). In 33 index cases with one or more exon deletions, nine (27%) developed one or more extracolonic features: duodenal adenomas (n ¼ 7), duodenal cancer (n ¼ 1), FGP (n ¼ 5), stomach polyps (n ¼ 1), CHRPE (n ¼ 1), desmoids (n ¼ 1) and epidermoid cysts (n ¼ 2).
Consequences for surveillance APC deletions show large intrafamilial as well as interfamilial variation in clinical phenotype, suggesting environmental and/or other genetic factors have a modifying influence. Consequently, advice for screening should not be based only on the extent and/or location of the mutation. As the mean age and range of CRC in patients with whole gene deletions is the same as for classic FAP patients, we advise screening according to FAP guidelines, 37 ie endoscopic colorectal screening every 2 years starting from age 10 to 12 years, and endoscopic screening of the upper gastrointestinal tract every 1 -5 years from age 25 to 30 years, depending on the findings. In those families with two or more members with an apparently attenuated phenotype, screening should start in the late teens. 38, 39 If there are more polyps than can be removed endoscopically, we advise performing a colectomy with ileorectal anastomosis, or a proctocolectomy with an ileoanal pouch anastomosis and follow-up screening of the rectum.
Conclusion
Using MLPA, we identified partial and total APC gene deletions in 6% (19/296) of patients who had previously undetected MUTYH and APC mutations; this represents 8% (19/242) of all the APC mutations found in our cohort of 599 polyposis patients. The majority of deletion patients displayed a classic polyposis phenotype, although we also identified three families with APC deletions (16%, 3/19) with a clearly attenuated FAP phenotype. We therefore recommend that MLPA should be used as a standard procedure for identifying APC mutations in polyposis patients with classic FAP as well as those with attenuated FAP.
